BBOT Announces New BBO-8520 Data; Highlights Strategic Focus on 2L+ NSCLC BBO-8520 Combination as Well as BBO-11818 and BBO-10203 Combinations in KRAS-Mutant Cancers
BBOT highlights strong BBO-8520 response rates in NSCLC, refocuses pipeline on KRAS-mutant combinations, and reports cash runway into 2028.
Rhea-AI Summary
BridgeBio Oncology Therapeutics (BBOT) reported new Phase 1 data for KRASG12C inhibitor BBO-8520 and outlined a sharpened development focus in KRAS-mutant cancers.
In 2L+ KRASG12C inhibitor-experienced NSCLC, BBO-8520 plus pembrolizumab achieved an objective response rate (ORR) of 75% at the 500 mg QD dose and 53% across all dose levels (N=17), with a generally tolerable, mainly GI-related safety profile and favorable liver safety. As monotherapy in 2L+ KRASG12C inhibitor-naïve NSCLC, BBO-8520 showed 63% ORR (26/41), 100% disease control (41/41), and no grade 3 liver enzyme elevations; 75% (21/28) of eligible patients remained on treatment beyond six months.
BBOT will prioritize BBO-8520 combinations in 2L+ inhibitor-experienced NSCLC and BBO-11818/BBO-10203 combinations in KRAS-mutant cancers. Cash and investments of $344.1 million as of June 30, 2026 are projected to fund operations into 2028, with multiple data readouts expected from late 2026 through mid-2027.
Positive
- BBO-8520 + pembrolizumab ORR 75% at 500 mg QD, 53% across doses (N=17) in 2L+ KRASG12C inhibitor-experienced NSCLC
- BBO-8520 monotherapy ORR 63% (26/41) with 100% DCR (41/41) in 2L+ KRASG12C inhibitor-naïve NSCLC
- Treatment durability: 75% (21/28) of eligible monotherapy patients remained on treatment beyond six months
- Safety: generally tolerable profiles reported; no grade 3 liver enzyme elevations with BBO-8520 monotherapy
- Liquidity: $344.1 million in cash, cash equivalents and marketable securities as of June 30, 2026
- Runway: funding projected to support operations into 2028 with multiple data catalysts through mid-2027
Negative
- None.
News Explained
BBOT reports that BBO-11818 and BBO-10203 combination cohorts are enrolling in KRAS-mutant colorectal and pancreatic cancers, adding a current trial-progress update.
Key Figures
- Combination ORR at 500 mg QD
- 75%
- BBO-8520 plus pembrolizumab; 2L+ KRASG12C inhibitor-experienced NSCLC
- Combination ORR across dose levels
- 53%
- BBO-8520 plus pembrolizumab; N=17
- Monotherapy ORR
- 63% (26/41)
- 2L+ KRASG12C inhibitor-naïve NSCLC
- Disease control rate
- 100% (41/41)
- BBO-8520 monotherapy in 2L+ NSCLC
- Treatment beyond six months
- 75% (21/28)
- Patients eligible for six-month follow-up
- Grade 3 liver enzyme elevations
- None
- BBO-8520 monotherapy safety profile
- Cash, cash equivalents and marketable securities
- $344.1 million
- As of June 30, 2026; projected runway into 2028
Historical Context
-
Reported continued BBO-8520 combination enrollment and $344.1 million cash balance.
-
Earlier BBO-8520 preliminary efficacy included 65% ORR and six-month PFS data.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
orr medical
nsclc medical
pdac medical
qd medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- BBO-8520 plus pembrolizumab demonstrated a
75% ORR at 500 mg QD and53% ORR across dose levels in 2L+ KRASG12C inhibitor-experienced NSCLC patients - BBO-8520 monotherapy continues to show highly competitive ORR in the 2L+ KRASG12C inhibitor-naïve NSCLC with ORR of
63% (26/41), disease control rate (DCR) of100% (41/41) and no grade 3 liver enzyme elevations - BBO-11818 and BBO-10203 combination cohorts enrolling in KRAS-mutant CRC and PDAC
$344.1 million in cash, cash equivalents and marketable securities as of June 30, 2026, provides runway into 2028
SOUTH SAN FRANCISCO, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced new clinical data for KRASG12C inhibitor BBO-8520 and the strategic prioritization of (i) BBO-8520 in combination with checkpoint inhibitor in 2L+ KRASG12C inhibitor-experienced non-small cell lung cancer (NSCLC) patients and (ii) BBO-11818 and BBO-10203 combinations in KRAS-mutant cancers.
“Across our portfolio, all three programs have now generated encouraging clinical data supporting further development, enabling us to focus our capital on the opportunities with the highest probability of success, clearest development paths, and greatest potential patient benefit,” said Pedro J. Beltran, Ph.D., Chief Executive Officer of BBOT. “With a strong balance sheet and multiple data catalysts through mid-2027, we believe BBOT is well positioned to advance differentiated therapies for patients with KRAS-driven cancers.”
BBO-8520 (Direct KRASG12C ON/OFF Inhibitor) Key Findings:
BBO-8520 is an oral, direct KRASG12C(ON/OFF) inhibitor. By directly inhibiting both the ON and OFF states of KRASG12C, BBO-8520 is designed to achieve potent pathway inhibition at lower free-drug exposures and enable combination with checkpoint inhibition. In the ongoing ONKORAS-101 (NCT06343402) Phase 1 study (data cutoff: June 1, 2026):
BBO-8520 in combination with pembrolizumab in NSCLC KRASG12C inhibitor-experienced patients showed:
- Objective response rate (ORR):
75% at the 500 mg once-daily (QD) dose level and53% across all dose levels (N=17). - Generally tolerable and manageable safety profile. Adverse events were primarily gastrointestinal (GI)-related, and a favorable liver safety profile was observed.
BBO-8520 monotherapy in 2L+ NSCLC KRASG12C inhibitor-naïve patients showed:
- ORR:
63% (26/41), with a disease control rate (DCR) of100% (41/41). - Among 28 patients eligible for a six-month follow-up,
75% (21/28) remained on treatment beyond six months. - Tolerable and manageable safety profile with no grade 3 liver enzyme elevations.
“The encouraging efficacy and safety profile with BBO-8520 plus pembrolizumab supports development in patients with KRASG12C-mutant NSCLC who have progressed on a prior G12C inhibitor, a growing population with significant unmet need,” said Yong (Ben) Ben, M.D., Chief Medical and Development Officer of BBOT.
Approximately 21,000 patients are expected to be diagnosed with NSCLC harboring KRAS G12C mutations in the United States in 2026. As G12C OFF-state inhibitors potentially move into the first-line setting, BBOT expects a growing population of patients who progress following treatment with a G12C inhibitor and for whom there is currently no approved targeted therapy.
Strategic Prioritization:
BBOT is focusing its capital and resources on opportunities that offer the highest probability of success and greatest potential benefit for patients:
- BBO-8520 in combination with pembrolizumab in 2L+, KRASG12C inhibitor-experienced NSCLC patients.
- BBO-11818 and BBO-10203 internal combination and independent combinations with standard of care agents in KRAS-mutant cancers.
Financial Position and Upcoming Milestones
As of June 30, 2026, BBOT had approximately
- BBO-11818 and BBO-10203 monotherapy data update in the fourth quarter of 2026.
- Expanded BBO-8520 plus pembrolizumab dataset in 2L+ KRASG12C inhibitor-experienced NSCLC expected in mid-2027.
- Data from BBO-11818 and BBO-10203 internal and standard-of-care combination cohorts in colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC) expected in mid-2027.
About BBOT
BBOT is a clinical-stage biopharmaceutical company advancing a next-generation pipeline of RAS-targeting small molecules. BBOT has the goal of employing novel therapeutic approaches to improve outcomes for patients with KRAS-driven cancers. For more information, please visit http://www.bbotx.com and follow us on LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as amended, and other federal securities laws. Any statements in this press release that are not historical facts may be deemed forward-looking statements, which generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” and similar expressions that predict or indicate future events or trends. These forward-looking statements include, without limitation, statements regarding the clinical and therapeutic potential and safety profile of BBOT’s product candidates, including BBO-8520, BBO-10203 and BBO-11818, as monotherapy or in combination with other therapeutics, the design and conduct of clinical trials with BBOT’s product candidates, including expected timelines for clinical data readouts, ongoing and planned regulatory interactions, BBOT’s plans to continue and expand its clinical trials, including its planned internal combination studies, the market opportunities and competitive landscape for BBOT’s product candidates, and BBOT's beliefs, expectations and assumptions regarding the future of its business, future plans and strategies, including statements regarding anticipated operating expenses, BBOT’s projected cash runway and sufficiency of its cash, cash equivalents and marketable securities to fund its operations.
These statements are based on various assumptions, whether or not identified in this press release, and are the current expectations of BBOT’s management and are not predictions of actual performance. Many actual events and circumstances are beyond the control of BBOT. These forward-looking statements are subject to a number of risks and uncertainties, including initial and interim data from BBOT’s clinical trials not being indicative or final data; the design, success and timing of ongoing and planned clinical trials; adverse events that may be encountered in BBOT’s clinical trials; risks relating to the uncertainty of the projected financial information with respect to BBOT; risks related to the regulatory review and potential approval of BBOT’s product candidates and the timing of expected regulatory and business milestones, including the progress of enrollment in clinical trials and availability of data from ongoing and planned clinical trials; the impact of competitive product candidates and commercial products; ability to obtain sufficient supply of materials; BBOT’s ability to maintain its existing agreements with third parties and to negotiate and enter into new definitive agreements on favorable terms, if at all; intellectual property-related claims; global economic and political conditions; changes in domestic and foreign business, market, financial, political, and legal conditions; and those other risks and uncertainties factors are described more fully in the “Risk Factors” section of BBOT’s most recent filings with the Securities and Exchange Commission and available at www.sec.gov.
In addition, forward-looking statements reflect BBOT’s expectations, plans, or forecasts of future events and views as of the date of this press release and are qualified in their entirety by reference to the cautionary statements herein. BBOT anticipates that subsequent events and developments will cause BBOT’s assessments to change. These forward-looking statements should not be relied upon as any guarantee, assurance, prediction or definitive statement of fact or probability or as representing BBOT’s assessments as of any date subsequent to the date of this press release. Neither BBOT, nor its affiliates undertake any obligation to update these forward-looking statements, except as required by law.
BBOT Contacts: Investor Contact: BBOT Investors@BBOTx.com Media Contact: Inizio Evoke Comms Jake.robison@inizioevoke.com
FAQ
What is BBO-8520 and how is it designed to work?
BBO-8520 is an oral, direct KRASG12C(ON/OFF) inhibitor. It is designed to inhibit both the active (ON) and inactive (OFF) states of KRASG12C, with the goal of achieving potent pathway inhibition at lower free-drug exposures and enabling combination with checkpoint inhibitors such as pembrolizumab.
What strategic programs is BBOT prioritizing based on these data?
BBOT is prioritizing:
- BBO-8520 plus pembrolizumab in 2L+ KRASG12C inhibitor-experienced NSCLC patients.
- BBO-11818 and BBO-10203 in internal combinations and in combinations with standard-of-care agents in KRAS-mutant cancers, including colorectal cancer and pancreatic ductal adenocarcinoma.
What upcoming clinical data readouts does BBOT expect?
BBOT expects:
- BBO-11818 and BBO-10203 monotherapy data update in the fourth quarter of 2026.
- An expanded BBO-8520 plus pembrolizumab dataset in 2L+ KRASG12C inhibitor-experienced NSCLC in mid-2027.
- Data from BBO-11818 and BBO-10203 internal and standard-of-care combination cohorts in colorectal cancer and pancreatic ductal adenocarcinoma in mid-2027.
What is BBOT’s current financial position and runway?
As of June 30, 2026, BBOT held approximately $344.1 million in cash, cash equivalents and marketable securities. The company projects this will fund operations into 2028.